Navigation Links
The Pill Comes Under the Spotlight

FDA advisors are planning to review existing birth control pills this week. This decision follows results from clinical studies that show the incidence of pregnancies to// have increased by twice over the last 10 years, while the subjects were on the pill.

Improper use, inferior products and other reasons are considered, as causes for this observation and the panel will discuss whether more stringent guidelines will be needed for safety and efficacy.

The Pill is the most popular method of the birth control in the U.S., accounting for more than 30 percent of all birth control use, according to the Mayo Clinic, while tubal sterilization, or the surgical blocking of a woman's fallopian tubes, is the second-most popular at 27 percent. Male condoms are next, at 18 percent.

Some 19 percent of all American women aged 15 to 44 use The Pill, according to the Centers for Disease Control. But many men and women don't use birth control at all, or they use it without success.

The outcome of these meetings could affect the 13 million-plus women and girls who take birth control pills in America, and the estimated $4 billion market for birth control drugs, dominated by Barr, Watson, Johnson and Johnson and Wyeth pharmaceuticals.

Pills approved in the 1960's allowed less than one pregnancy per 100 women taking the pill for a year. Newer pills allow over two pregnancies in a similar group of women.

Experts say this may be partly because new pills have fewer hormones that could lead to dangerous blood clots and heart disease.

The topics to be discussed by the FDA panel include: Clinical trial design issues, contraceptive efficacy and risk or benefit assessment cycle control (scheduled and unscheduled bleeding and spotting) and other measures of product acceptability to the user, translation of clinical trial findings of efficacy and safety into "real world" effectiveness and safety, extended dosing regimens, ph ase 4 commitments by applicants for further investigation, generally of uncommon but serious safety issues and role and impact of labeling for communication of clinical trial findings including product efficacy, risk, and other benefits.

FDA officials hope to use this information to create a guidance document for the clinical investigation of hormonal contraceptives.
ANN
'"/>




Related medicine news :

1. Lung Cancer: Nutritional Intervention Comes To The Rescue
2. Girl Comes Out Of Irreversible Coma
3. Poultry Owner Comes Up With Novel Idea To Boost Up Chicken Sales
4. Nurses Outsmart Surgeons When It Comes Safety And Team Wok
5. NICE Comes Under Attack
6. Yoga and Meditation Comes in Aid of Iraqis to Rid of Trauma
7. After Ecstasy Comes the Pain… WARNING
8. Ban On Trans Fats Comes Into Effect From July 1
9. Hospital Performance Measures May Not Make Much Difference When It Comes to Mortality
10. Sleeping Sickness Comes to India
11. Prolactin Comes to the Aid of MS Sufferers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... ... Journey: From the Mountains to the Mission Field”: the story of a missionary couple ... From the Mountains to the Mission Field” is the creation of published author, Carole ... and currently teaches a class of ladies at her church, which she has taught ...
(Date:10/12/2017)... San Francisco, CA (PRWEB) , ... October 12, ... ... and Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus ... sleep apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral ...
(Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... Washington, D.C. (PRWEB) , ... October 12, 2017 , ... ... of their peers in Washington, D.C., for the 49th Congress of the International ... Ph.D ., Vice President of the Center for Cancer and Blood Disorders ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... PARIS and NEW YORK , Sept. 12, ... ethical performance ratings for global supply chains, has published the first annual ... the CSR performance of more than 20,400 companies evaluated by EcoVadis, based ... years 2015 and 2016. ... EcoVadis Global CSR Risk & Performance Index ...
(Date:9/12/2017)... FRANCISCO , Sept. 12, 2017  ValGenesis ... Management Solutions (VLMS), is pleased to announce the ... a member of its Board of Directors and ... ValGenesis VLMS enables life science companies to manage ... the use of paper in this process. Furthermore, ...
(Date:9/9/2017)... , Sept. 8, 2017 Dealmed Medical ... independent supplier of medical equipment, supplies, drugs, vaccines, and ... has entered into an agreement to acquire Vantage Medical ... based in Holtsville, New York . ... in supplying new and emerging medical practices, will operate ...
Breaking Medicine Technology: